Amgen leads structurally, with profitability as the clearest single gap between the two profiles. Bristol-Myers Squibb Company still has the edge on valuation, which keeps the comparison from looking entirely one-sided. In the market, Bristol-Myers Squibb Company carries the stronger setup — intact trend against Amgen's broken trend. That leaves a split case: the structural lead stays with Amgen, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
Most of the separation is still concentrated in profitability. The overall score gap is 8 points in favour of Amgen Inc..
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. AMGN and BMY share the same industry classification.
For a similarity-based comparison, see how Amgen and BMY each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in profitability.
Left means cheaper relative valuation. Higher means stronger structure.
The setup splits cleanly: structure favours Amgen Inc., while the price setup favours Bristol-Myers Squibb Company.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where AMGN and BMY each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Return on equity adds support too, with a 63-point advantage.
Absolute pricing still looks more supportive for Bristol-Myers Squibb Company, with a forward P/E that is 4.7 turns lower there.
The page question resolves through profitability, but valuation and current pricing still keep the broader comparison from reading as fully aligned.
Break down the AMGN vs BMY comparison across all dimensions with the full interactive tool.
Explore how AMGN and BMY each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.